AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Veritone Inc. (VERI) slumped 15.61% in pre-market trading on Nov. 14, 2025, marking one of its steepest declines in recent months amid renewed skepticism over its AI-driven advertising platform’s scalability and revenue-generating potential.
Analysts attributed the sharp sell-off to investor concerns over the company’s ability to convert its AI technology into sustainable revenue streams. Recent earnings reports highlighted slower-than-expected adoption of its AI-powered ad verification tools, with clients citing integration complexities and limited ROI visibility. Short sellers also appeared to capitalize on the volatility, with open interest in bearish options contracts surging ahead of the session.
Technical indicators exacerbated the downward momentum. The stock’s 50-day moving average crossed below its 200-day line—a bearish “death cross” pattern—while the RSI entered oversold territory, suggesting potential for further weakness unless the company issues a strong earnings catalyst within the next two weeks. Traders are closely watching whether the $1.20 level holds as a near-term support.

Historical data shows Veritone’s stock has exhibited high volatility during earnings cycles, with average intraday swings exceeding 20% when revenue guidance deviates from expectations. This pattern underscores the stock’s sensitivity to sentiment shifts in the AI advertising sector.
Backtest assumptions suggest a neutral-to-bullish bias if the stock closes above $1.35 by Dec. 5, 2025. A long-position strategy initiated at $1.25 with a $1.15 stop-loss and $1.50 target would align with key Fibonacci retracement levels. However, failure to break the $1.30 psychological barrier could trigger additional profit-taking in short-term options and ETF exposure.
Get the scoop on pre-market movers and shakers in the US stock market.

Nov.26 2025

Nov.26 2025

Nov.26 2025

Nov.26 2025

Nov.26 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet